Evidence map›Paper›PMID 41158366›Full record

ArticleJournal of thoracic disease2025

Ten-year follow-up outcomes of resected stage II non-small cell lung cancer patients.

Wenrui Sun, Di Li, Yueren Yan, Han Han, Jinsong Bai, Zelin Ma, Fangqiu Fu, Yang Zhang, Haiquan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenrui Sun *Department of Thoracic Surgery, State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Di Li *Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China.
Yueren Yan *Department of Thoracic Surgery, State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Han Han *Department of Thoracic Surgery, State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Jinsong BaiDepartment of Thoracic Surgery, State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Zelin MaDepartment of Thoracic Surgery, State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Fangqiu Fu *Department of Thoracic Surgery, State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yang Zhang *Department of Thoracic Surgery, State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Haiquan Chen *Department of Thoracic Surgery, State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Stage II non-small cell lung cancer (NSCLC) comprises a diverse group of cancers with varying characteristics. This study aims to report the long-term outcomes of stage II NSCLC and gain insights into the potential benefits of adjuvant chemotherapy. Methods: Lung cancer patients who underwent surgery between November 2007 and December 2013 were reviewed. Clinicopathological characteristics were collected retrospectively. Post-operative survival and recurrence status were analyzed. Results: A total of 416 patients with stage II NSCLC were enrolled. The median follow-up period after surgery was 116 months. The overall survival rate at 5 and 10 years was 55.0%and 40.7%, respectively, while the recurrence-free survival rate at 5 and 10 years were 53.9% and 49.0%, respectively. Patients with stage II NSCLC receiving adjuvant chemotherapy had improved survival compared to those not receiving (log-rank P<0.001). Further subgroup analysis confirmed that the survival benefit from adjuvant chemotherapy was limited in IIB-N1/2a. For sub-group patients with high-risk factors (HRFs) in IIA or IIB-N0, adjuvant chemotherapy would improve survival as well. Conclusions: Our study presents long-term follow-up results for patients with stage II NSCLC, and our findings suggest that adjuvant chemotherapy is recommended for patients with stage IIA or IIB-N0 NSCLC who have HRFs, as well as for patients with stage IIB-N1/2a NSCLC.

Indexed as

adjuvant chemotherapylong-term prognosisNon-small cell lung cancer (NSCLC)stage II

Identifiers

PMID41158366
PMCPMC12557669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.